Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Study summary

The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPembrolizumab/Vibostolimab and Carboplatin

Plus 5 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · PD-L1 · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 11, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?149 U.S. locations

Locations may change over time.

Who runs it?Merck Sharp & Dohme LLC

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Merck Sharp & Dohme LLC
Interventions being studied: Biological: Pembrolizumab/Vibostolimab; Drug: Carboplatin; Drug: Cisplatin; Drug: Paclitaxel; Drug: Nab-paclitaxel; Drug: Pemetrexed; Biological: Pembrolizumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Biomarkers

PD-L1→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

The main inclusion and

Reasons someone may not be able to joinExclusion criteria

include but are not limited to the following: Inclusion Criteria:
A histologically or cytologically confirmed diagnosis of Stage IV squamous or non-squamous NSCLC
Has not received prior systemic treatment for metastatic NSCLC
Has measurable disease based on RECIST 1.1, as determined by the local site assessment
Has a life expectancy of at least 3 months
Males: Use contraception unless confirmed to be azoospermic; Females: Women of childbearing potential use highly effective contraceptive method

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

UCHealth Memorial Hospital-Heme Onc ( Site 0003)Colorado Springs, Colorado
University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0031)Fort Collins, Colorado
Mayo Clinic in Florida ( Site 0022)Jacksonville, Florida
Mount Sinai Hospital ( Site 0011)Chicago, Illinois
University of Chicago Medical Center ( Site 0015)Chicago, Illinois
New England Cancer Specialists ( Site 0008)Scarborough, Maine
Cancer and Hematology Centers of Western Michigan ( Site 0002)Grand Rapids, Michigan
Mayo Clinic in Rochester, Minnesota ( Site 0030)Rochester, Minnesota
Stony Brook University-Cancer Center ( Site 0013)Stony Brook, New York
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0012)Lancaster, Pennsylvania
Charleston Oncology ( Site 0019)Charleston, South Carolina
University of Virginia Cancer Center ( Site 0018)Charlottesville, Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 11, 2026. Always confirm current availability with the study team.

View original record ↗